Glimestar-M 2 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 2mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The combination of these agents provides complementary mechanisms of action, offering effective glycemic control in patients inadequately controlled by diet and exercise alone. Glimestar-M 2 Tablet PR is designed for prolonged release, ensuring a steady plasma concentration, which may improve patient compliance and reduce gastrointestinal side effects commonly associated with immediate-release formulations. This medication should be used as part of a comprehensive diabetes management plan that includes dietary modification, exercise, and regular monitoring of blood glucose levels. Contraindications include renal impairment, metabolic acidosis, and hypersensitivity to either component. Caution is advised in patients with hepatic dysfunction or cardiovascular disease. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. Regular monitoring of renal function and blood glucose is recommended during therapy to optimize safety and efficacy.